I'm Done With Citronella. This $35 Device Keeps Mosquitos at Bay Without the Odor
Longer, hotter summers means a longer mosquito season. If June's heat waves are any indication of what's to come, you better have a plan for bugs. I was winging it with fickle citronella and stinky bug spray until I discovered the Thermacell -- an affordable bug repellent diffuser that has kept my evenings almost completely bite-free since I started using it.
The Thermacell works better than any mosquito repellant I've tried.
David Watsky/CNET
Massachusetts-based Thermacell makes a line of devices designed to keep mosquitoes at bay by misting the air around with an odorless chemical that keeps bugs from biting. I tested the smallest of its devices, the Thermacell Radius E-series with fast charging dock, which defends pests in a 20-foot radius and costs just $40 on Amazon (currently on sale for $35), REI and other retailers.
How does the Thermacell work?
The rechargeable device releases a trickle of vapor, similar to an oil diffuser, that contains a synthetic version of a chemical found in the chrysanthemum flower. (The rechargeable Radius model uses metofluthrin; the other models use allethrin.) According to Griffin Dill, an integrated pest management professional at the University of Maine I spoke to, these compounds excite insects' neuroreceptors, which dissuades them from feeding. Because of this, you might still see bugs flying around but they're far less likely to bite you.
Thermacell
I also spoke with Thermacell's Senior Product Director Adam Goess, who performs research and testing in the company's sprawling laboratory in the swamps of Florida -- the mosquito capital of America. As of our speaking, they've found the device to be effective in deterring dozens of species of mosquitos and even black flies and biting gnats.
In my testing, it worked just as advertised. I ran the Thermacell around my outdoor dining table and lounge setup on five evenings during twilight when bugs are particularly ravenous. My yard has a pool, so you can only imagine the sort of swarms that descend on the space during summer.
Read more: Add These Bug-Repelling Plants to Your Kitchen Today
Each time, friends and I waited until we felt the first bites and broke out the Thermacell, placing it in the middle. In all five instances, the bug bites stopped as the mist made its way out of the softball-sized device. While bites were neutralized, we could still see the occasional mosquito darting about.
A few drawbacks
Pods last for about 36 hours and each one costs $20.
David Watsky/CNET
Thermacells are fueled by small pods. Those last for about 36 hours when run continuously before you'll need a refill. Refill pods cost about $20, but I found a two-pack, good for 72 hours of repelling, for $22 on QVC. Needless to say I jumped on the deal.
Considering the buggiest parts of the evening only last an hour or so, you can stretch a single pod for a month or more if you remember to turn it off when you're done or the bug hour is over. And only use it when you need it, not every time you hang outside.
Also, the Thermacell only works when it's charged and not while charging on the dock. So if you've forgotten to charge it before the bugs come, there's no recourse or backup plan and you'll have to wait until it regains some juice.
A Thermacell won't work while on its charging dock, so be sure that it's charged before the bug hour begins.
David Watsky/CNET
Though he hadn't tried the Thermacell himself, Dill said that he had heard good things from colleagues. He steered us away from a few other popular anti-mosquito products:
Those mosquito-repellent bracelets that look like old-fashioned telephone cords: They don't work.
Citronella candles: Those don't work.
Those organic essential oils favored by hippies like my wife: Dill wasn't willing to say they don't work, but he did point to the dearth of research about their efficacy and safety.
Amazon includes a Proposition 65 warning for California residents that discloses that Thermacell's repellent contains chemicals known to cause cancer and birth defects. Allethrin and metofluthrin are also toxic to some animals including birds, fish, bees and cats. Dill said that "though the potential for harm to humans is there, it's probably low," but he cautioned to use these devices in moderation and never indoors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to on-demand treatment in patients 12 years and older HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection that required minimal preparation NEW YORK, June 26, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous HYMPAVZI in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatment approaches are needed.1,2,3,4 Inhibitors, or antibodies, which neutralize factor replacement therapies and render them ineffective, may develop in people living with hemophilia.5 Inhibitors can be diagnosed with a blood test.6 Of the more than 800,000 people in the world living with hemophilia A or hemophilia B, approximately 20% of people with hemophilia A and 3% of people with hemophilia B are unable to continue taking factor replacement therapies because they develop inhibitors to FVIII (Factor VIII) and FIX (Factor IX) and these therapies no longer prevent or stop bleeding episodes.6,7 "Patients with inhibitors tend to face frequent complications, and navigating the treatment landscape can introduce complexities and increase disease burden,"1,2,3,4,8 said Davide Matino, M.D., BASIS Principal Investigator, Associate Professor of Medicine, McMaster University. "The strong bleed reduction with HYMPAVZI compared to on-demand treatment in the Phase 3 BASIS study, coupled with its weekly administration method, offers exciting potential for these patients who are in critical need of treatment options." The BASIS trial demonstrated that prophylactic treatment with HYMPAVZI resulted in a statistically significant and clinically relevant reduction in annualized bleeding rate (ABR) of treated bleeds in people living with severe hemophilia A or hemophilia B with inhibitors. Forty-eight people living with hemophilia were treated with HYMPAVZI during a 12-month period versus an on-demand intravenous regimen with bypassing agents, administered as part of usual care in the six-month lead-in period. HYMPAVZI was superior to on-demand treatment with a 93% reduction in ABR over 12 months (ABR 1.39 vs ABR on-demand 19.78; p < 0.0001). Superiority of HYMPAVZI was also demonstrated across all bleeding-related secondary endpoints—spontaneous bleeds, joint bleeds, target joint bleeds, and total bleeds. HYMPAVZI was generally well-tolerated, consistent with the non-inhibitor cohort of the BASIS study and Phase 1/2 results. No deaths or thromboembolic events were reported. "These encouraging results demonstrate HYMPAVZI's potential to help people living with hemophilia A or B with inhibitors, meeting an important need for patients with antibodies that neutralize most factor-based prophylactic options used to manage bleeding episodes," said Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer, Pfizer. "HYMPAVZI represents Pfizer's latest contribution in more than 40 years of working to advance hemophilia care, as a generally well-tolerated treatment option that could offer bleed protection with a straightforward, once-weekly subcutaneous administration in a pre-filled pen for patients with inhibitors, if approved in this patient population." Analyses of the full Phase 3 dataset from the inhibitor cohort of the BASIS study are ongoing, and additional data will be presented at upcoming medical meetings. Pfizer plans to discuss these data with regulatory authorities, with the goal of initiating regulatory filings for HYMPAVZI for the treatment of patients living with hemophilia with inhibitors. Discovered by Pfizer scientists, HYMPAVZI has a mechanism of action that is differentiated from FVIII and FIX replacement treatments. Instead of replacing missing or insufficient clotting factors, HYMPAVZI is intentionally designed to target tissue factor pathway inhibitor (TFPI), one of the body's natural mechanisms that inhibits the initiation of blood clotting. By targeting the Kunitz 2 domain of TFPI, HYMPAVZI may help re-establish balance between bleeding and blood clot formation with the goal of offering a combination of bleed protection, good tolerability, and straightforward administration. About the BASIS study The pivotal BASIS study is a global Phase 3, open-label, multicenter study to evaluate the efficacy and safety of HYMPAVZI in adolescent and adult participants ages 12 to <75 years with severe hemophilia A (defined as FVIII <1%) or moderately severe to severe hemophilia B (defined as FIX activity ≤2%) with or without inhibitors. This cohort included 48 people living with hemophilia with inhibitors who were treated with HYMPAVZI during a 12-month active treatment period (ATP) versus an on-demand intravenous regimen with bypassing agents, administered as part of usual care in a six-month observational period. During the ATP, participants received prophylaxis (a 300 mg subcutaneous loading dose of HYMPAVZI, followed by 150 mg subcutaneously once weekly) with potential for dose escalation to 300 mg once weekly. An additional three patients in the inhibitor cohort were on routine prophylactic treatment prior to the study and not included in the primary efficacy analysis. The primary endpoint measures the treated ABR during the 12-month ATP with HYMPAVZI compared to treated ABR on prior on-demand replacement therapy. For further information, visit About HYMPAVZI HYMPAVZI has received regulatory approvals in the U.S. and in Europe for eligible patients living with hemophilia A without factor VIII inhibitors, or hemophilia B without factor IX inhibitors. HYMPAVZI was the first anti-TFPI approved in the U.S. and EU for the treatment of hemophilia A or B and the first hemophilia medicine approved in the U.S. and EU to be administered via a pre-filled, auto-injector pen. For eligible people living with hemophilia B, it is the first once-weekly subcutaneous prophylactic treatment. HYMPAVZI can offer a subcutaneous treatment option with a once-weekly dosing schedule and minimal preparation required for each individual administration. Pfizer is also conducting BASIS KIDS, an open-label study investigating the safety and efficacy of HYMPAVZI in children 1 to <18 years of age with severe hemophilia A or moderately severe to severe hemophilia B with or without inhibitors. About Hemophilia Hemophilia is a family of rare genetic blood diseases caused by a clotting factor deficiency (FVIII in hemophilia A, FIX in hemophilia B), which prevents normal blood clotting. Hemophilia is diagnosed in early childhood and impacts more than 800,000 people worldwide.7 The inability of the blood to clot properly can increase the risk of painful bleeding inside the joints, which can cause joint scarring and damage. People living with hemophilia can suffer permanent joint damage following repeated bleeding episodes.9,10 For decades, the most common treatment approach for hemophilia A and B has been factor replacement therapy, which replaces the missing clotting factors. Factor replacement therapies increase the amount of clotting factor in the body to levels that improve clotting, resulting in less bleeding. The burden of intravenous infusions is believed to be a barrier to treatment adherence for some people living with hemophilia due in part to inconvenience, time constraints, and poor venous access.11 Approximately 20% of people with hemophilia A and 3% of people with hemophilia B are unable to continue taking factor replacement therapies because they develop inhibitors to FVIII and FIX.6 These patients often have higher treatment burden, including potential complications from bleeding such as hospitalization and death, as well as higher treatment-related costs.1,2,3,4,12 HYMPAVZI (marstacimab) U.S. Important Safety Information Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products (products that help blood clot but work in a different way than HYMPAVZI). You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI. Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you: have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery. have a severe short-term (acute) illness such as an infection or injury. are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI. You should use effective birth control (contraception) during treatment with HYMPAVZI and for at least 2 months after the last dose of HYMPAVZI. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI. are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. What are the possible side effects of HYMPAVZI? HYMPAVZI may cause serious side effects, including: blood clots (thromboembolic events). HYMPAVZI may increase the risk for your blood to clot. Blood clots may form in blood vessels in your arm, leg, lung, or head and can be life-threatening. Get medical help right away if you develop any of these signs or symptoms of blood clots: swelling or pain in arms or legs redness or discoloration in your arms or legs shortness of breath pain in chest or upper back fast heart rate cough up blood feel faint headache numbness in your face eye pain or swelling trouble seeing allergic reactions. Allergic reactions, including rash and itching have happened in people treated with HYMPAVZI. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction: swelling of your face, lips, mouth, or tongue trouble breathing wheezing dizziness or fainting fast heartbeat or pounding in your chest sweating The most common side effects of HYMPAVZI are injection site reactions, headache, and itching. These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. The full Prescribing Information can be found here. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at In addition, to learn more, please visit us on and follow us on X at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Disclosure notice The information contained in this release is as of June 26, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about HYMPAVZI™ (marstacimab), an anti-tissue factor pathway inhibitor, including its potential benefits and plans to discuss the Phase 3 BASIS data with regulatory authorities with the goal of initiating regulatory filings for HYMPAVZI for the treatment of patients living with hemophilia with inhibitors, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of HYMPAVZI; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed with regulatory authorities in particular jurisdictions for HYMPAVZI for any potential indication; whether and when any such applications that may be pending or filed for HYMPAVZI may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether HYMPAVZI will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of HYMPAVZI; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and 1 Shapiro AD, Ragni MV, Borhany M, et al. Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). Haemophilia. 2021;27(1):49-59. doi: 10.1111/hae.14139.2 Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia. 2004;10(2):134-46. doi: 10.1046/j.1365-2516.2003.00840.x.3 Nugent D, Kalnins W, Querol F, et al. Haemophilia Experiences, Results and Opportunities (HERO) study: Treatment-related characteristics of the population. Haemophilia. 2015;21(1):e26-38. doi: 10.1111/hae.12545.4 Soucie JM, Symons Jt, Evatt B, Brettler D, Huszti H, Linden J. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia. 2001;7(2):198-206. doi: 10.1046/j.1365-2516.2001.00484.x.5 Teiu P, Chan A, Matino D. Molecular Mechanisms of Inhibitor Development in Hemophilia. Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020001. doi: 10.4084/MJHID.2020.001.6 Centers of Disease Control and Prevention. Testing for Inhibitors and Hemophilia. Accessed May 14, 2025. Available at: World Federation of Hemophilia. World Federation of Hemophilia Global Report on the Annual Global Survey 2022. Meeks S, Batsuli G. Hemophilia and inhibitors: Current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):657–662. doi:10.1182/asheducation-2016.1.657.9 Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd Edition; 2020. Haemophilia. 26(S6), 1–158. Franchini M, Mannucci PM. Past, present and future of hemophilia: A narrative review. Orphanet J Rare Dis. 2012;7:24. Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133(5):389–398. Walsh CE, Soucie JM, Miller CH. Impact of inhibitors on hemophilia a mortality in the United States. Am. J. Hematol. 2015; 90: 400-405. Category: Medicines View source version on Contacts Media Contact:+1 (212) 733-1226PfizerMediaRelations@ Investor Contact:+1 (212) 733-4848IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
AI-Derived Risk Score May Improve Risk Stratification of Squamous Cell Carcinomas
An artificial intelligence (AI)-enabled prognostication system created through retrieval augmented generation (RAG) appears to offer significantly better predictive capability, particularly regarding poor outcomes, for cutaneous squamous cell carcinoma (cSCC) compared with the Brigham and Women's Hospital (BWH) and American Joint Committee on Cancer Staging Manual, Eighth Edition (AJCC8) systems, according to a recently published study. The authors say their model illustrates how targeted application of general-purpose large language models (LLMs) can help develop and refine future prognostication systems. Limited Guidance Neil K. Jairath, MD 'Currently,' Neil K. Jairath, MD, told Medscape Dermatology , 'up to 30% of bad outcomes in cSCC — recurrence, metastasis, and death — occur in what we classify as 'low-stage' tumors using existing systems, leaving practitioners with limited guidance for risk stratification.' Jairath is chief resident in dermatology at New York University, New York City, and is co-first author on the paper, which was published online on June 11 in JAMA Dermatology . To address the clinical-practice gap, he and his coauthors comprehensively searched PubMed, Embase, and the Cochrane Library, and selected 10 manuscripts for inclusion in an RAG knowledge base that informed creation of the model. Rather than relying solely on general training data, Jairath said, using RAG grounded the AI model in authoritative, domain-specific knowledge. 'This approach allowed us to leverage the collective insights from high-impact cSCC literature that represents decades of clinical research. Unlike purely AI-generated calculators that might produce unreliable outputs, RAG ensures our system is built on validated medical evidence,' he explained. Detailed prompting of a customized generative pretrained transformer (GTP-4, OpenAI) produced the AI-Derived Risk Score (AIRIS) prognostication system, which assigns 0-3 points to factors such as tumor diameter, depth, and the presence of immunosuppression. Total scores > 1 signify high-risk tumors. ** When validated on 2379 primary tumors, AIRIS demonstrated superior performance compared with the BWH and AJCC8systems across all key metrics. Most importantly, said Jairath, AIRIS showed dramatically improved sensitivity for identifying poor outcomes: 49% for local recurrence, 74% for nodal metastasis, and 83% for distant metastasis. The corresponding figures for BWH staging, the more reliable of the comparators, were 26%, 37%, and 38%. 'AIRIS's improved sensitivity means we can better identify high-risk patients who need enhanced surveillance or adjuvant therapy, while avoiding overtreatment of truly low-risk cases,' said Jairath. Although AIRIS prognostication showed the highest sensitivity for each outcome, it had the lowest specificity (85%-87%). 'We argue that this trade-off is clinically beneficial,' Jairath and colleagues wrote, 'as the magnitude increases in sensitivity across outcomes (nearly 20%-35%) appear to outweigh the loss of specificity (approximately 7% across outcomes).' In an accompanying editorial, authors led by Emily S. Ruiz, MD, MPH, academic director of the Mohs and Dermatologic Surgery Center at BWH in Boston, applauded AIRIS's clinically intuitive point-based system. Unlike current staging systems, these authors added, AIRIS assigns different point values to different risk factors. 'However,' they wrote, 'its formulation of several risk factors presents challenges for clinical applicability.' Although previous staging systems record invasive depth by tissue level, for example, the model uses millimeters. 'Translational research experience suggests that many molecular answers lie at the tumor's leading edge,' Jairath said. He referred to a study published in the Journal of Investigative Dermatology in 2014 that showed differential matrix metalloproteinase (MMP) profiles there, suggesting a possible contribution of interleukin-24 to SCC invasion through enhanced focal expression of MMP7. 'As we direct more translational efforts toward this interface,' he said, 'millimeter-level measurements may provide the granularity needed for molecular correlations and personalized therapy decisions.' Welcome Dialogue Veronica Rotemberg, MD, PhD The foregoing comments regarding millimeter-level measurements represent 'the kind of discussion that we must have when looking at different ways to incorporate AI into clinical practice,' said Veronica Rotemberg, MD, PhD, a dermatologist and director of dermatology informatics at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. She was not an author of the study or editorial but was the handling editor at JAMA Dermatology who focuses on AI papers. Presently, she said in an interview, if one queries an LLM about recurrence risk for a specific tumor, it is impossible to know what calculations produce the prediction. Instead, Rotemberg said, Jairath and colleagues used an LLM to create a transparent prognostication system. 'If you're an individual patient using this system, you're not using AI directly at all.' Patients and physicians can simply use the authors' table in the paper to tally points. 'You don't know exactly what went into generating this table,' Rotemberg said, 'although you mostly know because you know the papers that were used to inform it.' Nevertheless, she said it's too early to predict how AIRIS will impact clinical practice. Authors' validating the model on data not used to create or train it surpasses the validation efforts associated with many reported AI-enabled models, Rotemberg said. 'But the gold standard for any prediction model is prospective studies in its intended-use setting,' she added. 'We need to know, when faced with this scoring system, what decisions do people make, and how does that affect health?' For now, said Rotemberg, the study represents an exciting and necessary step in that direction. Going forward, Jairath said, he and his colleagues hope to expand AIRIS validation studies and would welcome the opportunity to test AIRIS on larger data sets. AIRIS study authors reported no funding sources but acknowledged the use of GPT-4 (OpenAI) as a base model. Jairath is CEO and cofounder of DermFlow and of Bedside Bike. He is also chief medical officer of AI Regent and an advisor to Marit Health. Rotemberg is an associate editor for AI of JAMA Dermatology but did not author the AIRIS study or editorial. Her comments do not represent the views of MSKCC. Ruiz is a consultant for Regeneron, Checkpoint Therapeutics, Feldan Therapeutics, and Merck. Additionally, she is an investigator for Regeneron, Castle Biosciences, and Merck. Editorial coauthor William Lotter, PhD, of the Dana-Farber Cancer Institute in Boston reported receiving personal fees from SpringTide Ventures and Servier, nonfinancial support from Dekang Medical, and grants from the National Institute of Biomedical Imaging and Bioengineering. John Jesitus is a Denver-based freelance medical writer and editor.
Yahoo
an hour ago
- Yahoo
WATCH: Axiom-4 crew docks with ISS
The crew of Axiom Mission 4 docked Thursday morning with the International Space Station. SpaceX said the docking happened at 6:31 a.m. EST. The four astronauts traveled to ISS for a little over a day in their new Dragon spacecraft named 'Grace.' It lifted off on a Falcon 9 rocket at 2:31 a.m. Wednesday from Kennedy Space Center. The team will spend about two weeks on the ISS, running nearly 60 experiments from 31 countries. Monitor and watch Eyewitness News for regular updates on the Axiom Mission 4. Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.
